A shadow economy for unlicensed weight-loss medications is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.
Investigational Treatment Acquiring Popularity Via Social Media
Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its supposed fat-burning effects. Followers are encouraged to contact these profiles directly for source information, while also obtaining promotional offers.
Thriving Commerce on Messaging Platforms
Separately, a robust trade exists on messaging services, where communities with numerous of members share comparison photos, administration instructions and claims of rapid UK delivery. Vendors promote the drug there before redirecting customers to WhatsApp for transactions.
Understanding Retatrutide
Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist patients lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed digitally as the next Ozempic.
Healthcare Professionals Voice Concerns
However, doctors and pharmacists have warned that the distribution of what remains an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals administering substances of unknown origin.
Some professionals said the popularity for retatrutide could be connected to the increasing price of licensed slimming products such as Mounjaro.
Regulatory Status and Enforcement
Marketing the unapproved drug on TikTok or Telegram is prohibited in the UK, as it is an unlicensed drug that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.
Several content creators attempt to circumvent the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but advertising and supply can still violate medicines, advertising, and consumer laws, risking fines, legal action or imprisonment.
Service Reaction and Content Elimination
According to the social media company, the platform has removed violative material and prohibited associated keywords and query recommendations. The organization stated it was dedicated to maintaining the service secure and allocating resources in strengthening compliance measures.
Online Trading Activities
Investigations also found groups with up to nine thousand participants selling the experimental drug using the platform's built-in discovery tool, which operates like a public directory. Entering “retatrutide” instantly brings up groups with thousands of members, filled with photos of weight loss, positive reviews and step-by-step instructions for preparing or injecting at home.
After moments of joining one group, a seller posted contact information, where the majority of purchases occur. The vendor provided an instruction manual and promised shipping within 48 hours. When questioned whether the product was authentic, one seller responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. Not one inquired about weight, medical conditions or past usage.
Product Information and Costs
Inside these communities, messages display dark colored parcels with postal service labels, claiming to include new batches. One message read: “It took eight of us to load them this morning.”
Buyers can select between powder vials, prepared at residence with sterile water, or pre-filled injectors usually priced at £160 for 20 milligrams. When questioned how long a pen should last, sellers give conflicting responses ranging from a few weeks to “depends on your body”.
Service Moderation and Security Actions
A representative for Telegram said it actively moderated harmful content on its platform including content that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“Individuals are administering substances they can’t verify. Although the science behind this drug is valid, these digital versions may not include what they claim,” said a pharmacy expert, the director of pharmaceutical services at a pharmacy service.
A medical professional of an online medical service connected the increase in demand to current cost increases for authorized weight-loss drugs such as Mounjaro. “With prices increasing, patients are using social media. But fake treatments are highly risky. You can’t be certain what’s contained or whether the environment they were made in was sterile,” she explained.
Her staff has already seen individuals harmed by personal administration from unconfirmed suppliers. “We understand the frustration, but purchasing from messaging apps or communication platforms is taking chances with your health,” said the doctor. “These materials could be impure or incorrectly dosed.”
Producer Position
A representative from Eli Lilly said retatrutide was in third stage clinical trials and had not been evaluated or authorized by any government authority globally. “Consequently at this point no one can sell [it] for human use,” they explained, noting that any item “misleadingly claiming itself as a company investigational substance not yet approved … may expose patients to potentially significant health risks”.
